Lv5
1586 积分 2021-05-31 加入
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models
3天前
已完结
Discovery of Novel Class of METTL3 Inhibitors with a Pyridin-2(1 H )-one Moiety
3天前
已完结
siRNA: Mechanism of action, challenges, and therapeutic approaches
4天前
已完结
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective
9天前
已完结
siRNA-based delivery systems: Technologies, carriers, applications, and approved products
10天前
已完结
Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells
14天前
已完结
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
24天前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
30天前
已完结
Emerging IgE and non-IgE targeted therapies for chronic urticaria
1个月前
已完结
Basic mechanisms of itch and advances in clinical management
2个月前
已完结
皖公网安备34019202002308
